首页> 外文期刊>Journal of the American College of Surgeons >Peripheral vascular surgery using targeted Beta blockade reduces perioperative cardiac event rate.
【24h】

Peripheral vascular surgery using targeted Beta blockade reduces perioperative cardiac event rate.

机译:使用靶向β受体阻滞剂进行外周血管手术可降低围手术期心脏事件发生率。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Recent studies suggest that preoperative cardiac stress testing is unnecessary in low to intermediate cardiac risk patients undergoing operations, and that targeted beta blockade is cardiac protective. STUDY DESIGN: A cohort study of patients undergoing vascular surgery or major amputation, with low to intermediate cardiac risk, but without cardiac stress testing, was performed. Targeted beta blockade was initiated preoperatively. The primary end point was a composite of adverse cardiac outcomes. A comparison was made with historical controls who received selective stress testing and selective nontargeted beta blockade. RESULTS: One hundred consecutive patients were prospectively enrolled, and 80 retrospective controls were identified. There were no differences between groups with respect to median revised cardiac index (RCI; 0 versus 1). In the retrospective group, 14% underwent preoperative cardiac stress testing versus none in the prospective group (p=0.0002). Nontargeted beta blockade was given in 61% of the retrospective group. The median heart rate for the prospective group was significantly lower (66 versus 77 beats/minute; p=0.0007). The composite cardiac complication rate was 2% in the prospective group versus 10% in the retrospective group (p=0.02). There were no deaths. On multivariate analysis, after adjusting for revised cardiac index score, there was a lower cardiac complication rate in the prospective group (odds ratio, 2.46; 95% CI, 1.3 to 4.5; p=0.003). CONCLUSIONS: In patients undergoing vascular surgery or major amputation, with low to intermediate cardiac risk, preoperative targeted beta blockade alone is more effective than selective cardiac stress testing and nontargeted beta blockade in preventing cardiac morbidity.
机译:背景:最近的研究表明,对于正在接受手术的中低心脏病风险的患者,术前无需进行心脏压力测试,并且靶向β受体阻滞剂具有心脏保护作用。研究设计:对接受血管外科手术或大面积截肢的患者进行了队列研究,这些患者具有低至中度心脏风险,但未进行心脏压力测试。术前开始有针对性的β受体阻滞剂。主要终点是不良心脏预后的综合指标。与接受选择性压力测试和选择性非靶向β受体阻滞剂的历史对照组进行比较。结果:连续入选了一百例患者,并确定了80例回顾性对照。两组之间在中位修正心脏指数方面没有差异(RCI; 0对1)。在回顾性组中,有14%接受了术前心脏压力测试,而在预期组中则没有进行(p = 0.0002)。回顾性组中有61%给予了非靶向的β受体阻滞剂。前瞻性组的中位心率显着降低(66次/ 77次/分钟; p = 0.0007)。前瞻性组的复合心脏并发症发生率为2%,回顾性组为10%(p = 0.02)。没有死亡。在多变量分析中,校正校正后的心脏指数评分后,预期组的心脏并发症发生率较低(优势比为2.46; 95%CI为1.3至4.5; p = 0.003)。结论:在进行血管外科手术或大面积截肢的患者中,心脏风险低至中度,术前靶向β受体阻滞剂比预防性心脏压力测试和非靶向β受体阻滞剂更有效地预防心脏疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号